Transmembrane protein 16A--a new target for the treatment of airway inflammatory diseases.
10.13201/j.issn.2096-7993.2025.06.017
- Author:
Qiulan LUO
1
;
Ningcong XU
1
;
Xi TAN
2
Author Information
1. Department of Otorhinolaryngology，the Affiliated Traditional Chinese Medicine Hospital，Guangzhou Medical University.
2. Department of Otorhinolaryngology Head and Neck，the Second Affiliated Hospital of Guangzhou University of Chinese Medicine，Guangzhou，510120，China.
- Publication Type:English Abstract
- Keywords:
allergic rhinitis;
asthma;
chronic sinusitis;
pulmonary cystic fibrosis;
transmenbrane protein 16A
- MeSH:
Humans;
Asthma/metabolism*;
Anoctamin-1;
Cystic Fibrosis/metabolism*;
Neoplasm Proteins/metabolism*;
Sinusitis/metabolism*;
Chloride Channels/metabolism*;
Rhinitis, Allergic/metabolism*;
Inflammation
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2025;39(6):590-596
- CountryChina
- Language:Chinese
-
Abstract:
One of the main pathological features of airway inflammatory diseases is hypersecretion of airway mucus, which is manifested by goblet cell hyperplasia and mucociliary clearance dysfunction. In recent years, it has been found that the molecular structure of calcium activated chloride ion channels, transmenbrane protein 16A（TMEM16A）, is closely related to airway mucus hypersecretion.TMEM16A not only mediates ion transepithelial transport and hydration, but also participates in the regulation of mucin secretion. TMEM16A is highly expressed in airway epithelium of a variety of inflammatory diseases of upper and lower airway, such as asthma, cystic fibrosis, allergic rhinitis, chronic sinusitis and so on. Understanding the expression level and regulation mechanism of TMEM16A in different airway diseases and revealing its physiological function and pathological mechanism is critical for targeted disease treatment. This paper summarizes the research status of the discovery process, structural characteristics and regulatory mechanism of TMEM16A, and then summarizes the expression level of TMEM16A in asthma, cystic fibrosis, allergic rhinitis and chronic sinusitis ant related pathological mechanisms, clarifies the potential value of TMEM16A as a therapeutic target for the above four diseases, in order to guide treatment of airway inflammatory diseases.
